Haleon Pakistan Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0112101016
PKR
725.46
-9.78 (-1.33%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Haleon Pakistan Ltd. stock-summary
stock-summary
Haleon Pakistan Ltd.
Pharmaceuticals & Biotechnology
Glaxosmithkline Consumer Healthcare Pakistan Limited is a Pakistan-based pharmaceutical company, which provides patient-focused medical solutions. It is engaged in manufacturing and marketing of research based ethical specialties, other pharmaceutical and consumer products. Its segments include Pharmaceuticals and Consumer Healthcare. Its Pharmaceuticals segment includes prescription drugs and vaccines, and consumer healthcare segment includes over-the-counter-medicines, oral care and nutritional care. It deals in Antiinfective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular and Vitamins therapy areas. Its pharmaceutical brands include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol, and consumer healthcare brands include Panadol, Horlicks, Sensodyne and ENO. Its Global Manufacturing Services in Pakistan consists of three facilities, including West Wharf, F-268 site and Korangi.
Company Coordinates stock-summary
Company Details
Sykes Building 35-Dockyard Road,, West Wharf KARACHI None : 74000
stock-summary
Tel: 92 21 111475725
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Sohail Matin
Chief Executive Officer, Executive Director
Mr. Dilawar Meghani
Chief Financial Officer, Executive Director
Mr. Oussama Abbas
Non-Executive Director
Mr. Talal Ahmed
Non-Executive Director
Ms. Erum Shakir Rahim
Non-Executive Director
Mr. Syed Anwar Mahmood
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
10,030 Million
(Quarterly Results - Mar 2025)
Net Profit:
1,348 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PKR 96,843 Million (Large Cap)

stock-summary
P/E

19.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

3.63%

stock-summary
Debt Equity

-0.43

stock-summary
Return on Equity

43.68%

stock-summary
Price to Book

7.10